Article
Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.
BMC pharmacology & toxicology - 13 Jun 2026
Xajil-Ramos Lesly Yanira, Gándara-Mireles Jesús Alonso, Guerra-García Mariela, Rosales Rodrigo José Vargas, Toledo Andrea Mariela Ruano, Ocaña-Garrido Dulce Sofia, Lares-Asseff Ismael, Cóbar Oscar, Soveranis Sindy Méndez, Patrón-Romero Leslie, Almanza-Reyes Horacio, Lou-Meda Randall
Abstract excerpt
BACKGROUND: Population pharmacokinetics and pharmacogenomics are essential tools for understanding interindividual variability in tacrolimus exposure in pediatric transplant recipients. Identifying clinical and genetic factors associated with tacrolimus disposition may support individualized dosing strategies. This study aimed to develop a population pharmacokinetic (PopPK) model of tacrolimus in pediatric renal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.